Back to top

Analyst Blog

Bristol-Myers Squibb Company (BMY - Analyst Report) presented encouraging data on its HIV candidate BMS-663068 (an attachment inhibitor) at the 21st conference on retroviruses and opportunistic Infections. The phase IIb study (n=254) evaluated the candidate in treatment experienced HIV-1 infected adults across four doses - (400 mg (twice daily); 800 mg (twice daily); 600 mg (once daily); 1200 mg (once a day)).

Data from the 24 week study revealed that BMS-663068 was as effective as the biopharma major’s established HIV treatment Reyataz (boosted with AbbVie Inc.’s (ABBV - Analyst Report) Norvir) in controlling the dreaded virus. Bristol-Myers said that treatment with BMS-663068 reduced the level of the virus to undetectable levels in 69%–80% patients, while Norvir boosted Reyataz therapy achieved similar results in 75% patients. Moreover, the candidate was found to be well tolerated in the study. No patient opted out of the study due to adverse events.

The positive results from the study are highly encouraging as successful development and subsequent commercialization of the candidate would enlarge the treatment options for HIV patients who have failed other therapies. In the event of the candidate entering the market, Bristol-Myers’ top line would be boosted as the HIV market is lucrative. Bristol-Myers is also developing Reyataz and Gilead Sciences’ (GILD - Analyst Report) cobicistat as a fixed dose combination to treat HIV patients.

According to the company, HIV affects 34 million people across the globe. Apart from Bristol-Myers, many other companies such as Merck & Co. (MRK - Analyst Report) are developing candidates to treat HIV.

Bristol-Myers carries a Zacks Rank #3 (Hold). A better-ranked stock in the biopharma space is Gilead Sciences which carries a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
QIHOO 360 T… QIHU 95.04 +4.95%
PILGRIM'S P… PPC 31.52 +3.72%
CLAYTON WIL… CWEI 138.97 +3.55%
CALLON PETE… CPE 11.50 +3.14%
ACTELION LT… ALIOF 124.80 +2.97%